| Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic … TM Kadia, PK Reville, G Borthakur, M Yilmaz, S Kornblau, Y Alvarado, ... The Lancet Haematology 8 (8), e552-e561, 2021 | 152 | 2021 |
| Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy HA Abbas, D Hao, K Tomczak, P Barrodia, JS Im, PK Reville, Z Alaniz, ... Nature communications 12 (1), 6071, 2021 | 94 | 2021 |
| Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells GB Lesinski, PK Reville, TA Mace, GS Young, J Ahn-Jarvis, ... Cancer Prevention Research 8 (11), 1036-1044, 2015 | 94 | 2015 |
| Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia TM Kadia, PK Reville, X Wang, CR Rausch, G Borthakur, N Pemmaraju, ... Journal of Clinical Oncology 40 (33), 3848-3857, 2022 | 76 | 2022 |
| Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis HE Cummings, J Barbi, P Reville, S Oghumu, N Zorko, A Sarkar, ... Proceedings of the National Academy of Sciences 109 (4), 1251-1256, 2012 | 63 | 2012 |
| Neuroblastoma patients' KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children's Oncology Group AK Erbe, W Wang, L Carmichael, KM Kim, EA Mendonça, Y Song, D Hess, ... Clinical Cancer Research 24 (1), 189-196, 2018 | 60 | 2018 |
| Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML M Yilmaz, H Kantarjian, NJ Short, P Reville, M Konopleva, T Kadia, ... Blood cancer journal 12 (5), 77, 2022 | 56 | 2022 |
| HLA and MICA allosensitization patterns among patients supported by ventricular assist devices M Askar, E Hsich, P Reville, AS Nowacki, W Baldwin, S Bakdash, ... The Journal of Heart and Lung Transplantation 32 (12), 1241-1248, 2013 | 56 | 2013 |
| Utility of protocol kidney biopsies for de novo donor-specific antibodies S Parajuli, PK Reville, TM Ellis, A Djamali, DA Mandelbrot American Journal of Transplantation 17 (12), 3210-3218, 2017 | 52 | 2017 |
| Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study CA Lachowiez, PK Reville, H Kantarjian, E Jabbour, G Borthakur, N Daver, ... The Lancet Haematology 9 (5), e350-e360, 2022 | 48 | 2022 |
| Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study PK Reville, HM Kantarjian, F Ravandi, E Jabbour, CD DiNardo, N Daver, ... Blood cancer journal 11 (3), 60, 2021 | 39 | 2021 |
| Maintenance Therapy in AML PK Reville, TM Kaida Frontiers in Oncology 10, 3255, 2020 | 35 | 2020 |
| HLA and MICA polymorphism in Polynesians and New Zealand Maori: implications for ancestry and health HA Edinur, PPJ Dunn, L Hammond, C Selwyn, P Brescia, M Askar, ... Human immunology 74 (9), 1119-1129, 2013 | 33 | 2013 |
| Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab AK Erbe, W Wang, L Carmichael, A Hoefges, B Grzywacz, PK Reville, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 25 | 2019 |
| Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment CA Lachowiez, PK Reville, H Kantarjian, E Jabbour, G Borthakur, N Daver, ... American journal of hematology 97 (11), 1443-1452, 2022 | 24 | 2022 |
| HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy AK Erbe, W Wang, PK Reville, L Carmichael, KM Kim, EA Mendonca, ... Frontiers in immunology 8, 675, 2017 | 22 | 2017 |
| Clinical and molecular characterization of myeloid sarcoma without medullary leukemia HA Abbas, PK Reville, A Geppner, CR Rausch, N Pemmaraju, M Ohanian, ... Leukemia & lymphoma 62 (14), 3402-3410, 2021 | 21 | 2021 |
| Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion PN Desai, B Wang, A Fonseca, P Borges, FZ Jelloul, PK Reville, E Lee, ... Cancer immunology research 11 (7), 1011-1028, 2023 | 20 | 2023 |
| Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy … PK Reville, K Sasaki, HM Kantarjian, NG Daver, M Yilmaz, CD Dinardo, ... American journal of hematology 97 (3), 329-337, 2022 | 19 | 2022 |
| BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor W Fiskus, J Piel, M Collins, M Hentemann, B Cuglievan, CP Mill, ... Blood 143 (20), 2059-2072, 2024 | 14 | 2024 |
Guillermo Garcia-ManeroMD Anderson Cancer CenterVerified email at mdanderson.org